Saturday 17 October 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.87
0.25
−6.07%
Follow TMCI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.95 | 0.73 | 0.42 | 1.26 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(46.88) | (19.31) | 11.96 | (55.11) | |
P/B ratio |
4.78 | 1.77 | 1.12 | 3.82 | |
Price to Tangible BV |
6.18 | 2.30 | 1.51 | 5.36 | |
EV/Sales |
1.94 | 0.77 | 0.45 | 1.32 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(34.90) | (10.27) | (7.14) | (18.60) | |
EV/FCF |
(16.10) | (5.56) | (3.56) | (10.82) | |
Quick Ratio |
2.21 | 2.95 | 2.38 | 1.79 | |
Current Ratio |
3.37 | 4.31 | 3.58 | 2.90 | |
Net Debt/EBITDA |
0.30 | (2.37) | (0.25) | (0.81) | |
Debt/Assets |
27.23% | 29.17% | 30.32% | 30.95% | |
Debt/Equity |
0.60 | 0.64 | 0.72 | 0.83 | |
Asset Turnover |
1.07 | 1.04 | 1.06 | 1.06 | |
Operating CF/Net income |
0.56 | 0.85 | (0.40) | 0.30 | |
Capex/Depreciation |
(0.99) | (0.83) | (2.63) | (1.03) | |
Interest Coverage |
(11.72) | (4.39) | (10.93) | (9.58) | |
Research and Development Expense of Revenue |
9.32% | 7.26% | 9.79% | 9.64% | |
Selling, General and Administrative Expense of Revenue |
100.97% | 82.82% | 105.83% | 101.79% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.11 | 0.11 | |
Share Based Compensation of Revenue |
15.93% | 12.08% | 17.02% | 14.24% | |
Graham Net Nets |
0.07 | 0.19 | 0.19 | 0.03 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.92%) | (38.37%) | (72.39%) | (23.37%) | |
Free Cash Flow Yield |
(6.18%) | (19.02%) | (30.00%) | (9.67%) | |
Revenue per Share |
0.79 | 0.99 | 0.73 | 0.70 | |
Operating CF per Share |
(0.14) | (0.13) | 0.11 | (0.07) | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.03) | |
Free Cash Flow per Share |
(0.19) | (0.16) | 0.06 | (0.11) | |
Cash per Share |
0.90 | 0.76 | 0.80 | 0.70 | |
Shareholders Equity per Share |
1.40 | 1.38 | 1.20 | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.40 | 1.38 | 1.20 | 1.04 | |
Free Cash Flow |
(11.90) | (10.42) | 4.18 | (6.90) | |
Working Capital |
97.09 | 101.42 | 88.98 | 78.96 | |
Capital Expenditures |
(2.81) | (2.40) | (3.06) | (2.20) | |
Net Current Asset Value |
30.59 | 28.81 | 16.56 | 7.14 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.04 | 0.06 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
28.57 | 41.48 | 30.73 | 29.53 | |
Average Payables |
17.38 | 8.62 | 13.38 | 18.01 | |
Average Inventory |
42.52 | 37.64 | 37.15 | 40.97 | |
Average Assets |
204.76 | 203.84 | 194.97 | 193.75 | |
Average Common Equity |
97.05 | 100.11 | 91.27 | 82.68 |
Columns are period end dates